To reactivate the cytotoxic T cells and enhance their tumor killing ability, apart from PD-1/PD-L1 blockade, another feasible approach is to directly downregulate the expression of PD-L1, which would reduce the chance of interactions with its counterpart and diminish the intrinsic negative functions for anti-tumor immunity. This evidence concerns the gene PDCD1 and neoplasm.